Tylenol Autism ADHD Lawsuit | Acetaminophen During Pregnancy Linked to Birth Defects

Tylenol Autism ADHD Lawsuit | Acetaminophen During Pregnancy Linked to Birth Defects

Scientific research has found that the use of Tylenol during pregnancy may increase a child’s risk of developing autism, ADHD, and other developmental disorders.

New Tylenol autism ADHD lawsuit claims are being brought against the manufacturers of the drug on behalf of children injured as a result of their mother’s use of Tylenol during pregnancy.

The Tylenol lawsuit alleges McNeil Consumer Products, a subsidiary of Johnson & Johnson, failed to warn consumers of dangers associated with the drug.

If you or a loved one used Tylenol while pregnant, and your child was subsequently diagnosed with Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD), you may be eligible to file a claim.

Use the chatbot on our page for a free case review and consultation to see if you qualify for legal action today.

Table of Contents

Lawsuit Updates

  • February 2024 Updates:

    February 5th, 2024:

    A group of twelve parents and children, alleging prenatal acetaminophen exposure caused ADHD, seeks to challenge the disqualification of expert witnesses. They argue for the right to present their own experts in multidistrict litigation, following a ruling that nullified expert testimony for similar cases.

    This prior decision left many plaintiffs without credible evidence linking Tylenol or similar products to autism or ADHD. U.S. District Judge Denise Cote demands justification for the continuation of their cases. The claim is supported by a 3rd Circuit precedent affirming the right to individual assessment of cases in MDLs.

  • January 2024 Updates:

    January 15th, 2024:

    In the ongoing saga of the MDL, the 501 plaintiffs involved have decided to appeal Judge Cote’s ruling. Additionally, some plaintiffs are exploring alternative options by turning to state court avenues. Among plaintiffs’ lawyers, there is a significant discourse regarding strategies to approach the litigation in state courts, including deliberations on the most favorable jurisdictions for filing suits.

  • December 2023 Updates:

    December 21st, 2023:

    A decision by U.S. District Judge Denise Cote has barred expert witnesses from testifying that the consumption of Tylenol, produced by Kenvue, a spin-off of Johnson & Johnson, can lead to autism during pregnancy due to a lack of credible scientific evidence to substantiate these claims.

    This ruling is likely to bring an end to a large-scale mass tort litigation comprising approximately 500 lawsuits against Tylenol.

    Judge Cote concluded that the expert witnesses for the plaintiffs failed to provide a solid scientific foundation for their assertion that the active ingredient in Tylenol, acetaminophen, could result in autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).

    In response to this decision, Kenvue plans to dismiss all pending cases, and its stock has experienced a roughly 4% increase following the ruling.

    The lawsuits also targeted retailers selling generic versions of Tylenol, but these retailers have not issued any statements regarding the verdict.

    These lawsuits hinged on the use of expert testimony, emphasizing the importance of adhering to scientific standards when presenting such evidence.

    While some studies have suggested a potential connection between the use of acetaminophen during pregnancy and the mentioned disorders, researchers caution that other variables may be contributing factors, necessitating further investigation.

    Health experts recommend acetaminophen over aspirin or ibuprofen for pregnant women due to potential fetal organ damage associated with the latter two medications.

    December 6th, 2023:

    If Judge Cote does not reject the defendants’ Daubert challenges soon, it could result in a significant increase in the backlog of cases within the Tylenol autism MDL.

    In just the past month, an additional 58 cases have been added, bringing the total count to 441.

    Additionally, there is a conference scheduled for January 4, 2024, at 4:30 p.m. to address the potential settlement arrangement in the Tylenol class action lawsuit.

  • November 2023 Updates:

    November 17th, 2023:

    In the past month, fifty-eight new cases have been incorporated into the Tylenol autism class action MDL, bringing the total number of pending cases to 441.

    Should Judge Cote reject the defendants’ Daubert challenges, the quantity of pending cases within the MDL is anticipated to undergo a substantial increase.

    November 11th, 2023:

    a Daubert hearing is scheduled for December 7, 2023, but it will proceed without the inclusion of witnesses.

    November 6th, 2023:

    All briefs under Daubert, focusing on the acceptance of scientific expert testimony, have been presented to Judge Cote.

    Both sides have submitted additional memorandums backing their requests to disqualify specific expert witnesses proposed by the other party.

    These reply documents address the arguments raised by the opposing side in response to the initial motions for exclusion.

    Each expert witness has their own extensive brief, along with supporting exhibits, amounting to several thousand pages throughout three rounds of briefings.

    Judge Cote is preparing to conduct hearings to review these motions and might directly interact with some of the experts.

    A hearing is scheduled for the week commencing December 5, 2023.

    November 1st, 2023:

    Daubert briefs regarding the admissibility of scientific expert testimony have been filed with Judge Cote. Both parties submitted reply memorandums last week to support their motions to exclude specific expert witnesses.

    These replies respond to arguments made by the opposing side in response to the initial exclusion motions. Separate briefs were filed for each expert witness, totaling several thousand pages with supporting exhibits.

    The next step involves hearings in which Judge Cote will evaluate the arguments and may directly engage with some of the experts.

  • October 2023 Updates:

    October 27th, 2023:

    Rite-Aid Corporation has filed for Chapter 11 bankruptcy protection due to the significant costs of opioid epidemic lawsuits and recent revenue losses.

    The bankruptcy petition was submitted to the U.S. Bankruptcy Court for the District of New Jersey, as Rite-Aid is facing unresolved lawsuits related to its involvement in the opioid abuse crisis.

    Rite-Aid is also entangled in Tylenol lawsuits, where it is alleged that over-the-counter acetaminophen products used during pregnancy can increase the risk of autism or ADHD.

    Plaintiffs plan to confer with the company’s bankruptcy counsel to discuss how the bankruptcy proceedings will affect the ongoing litigation.

    The remaining cases are anticipated to go through a bellwether process to assess how juries might react to specific evidence, potentially influencing future Tylenol settlements.

    October 11th, 2023:

    In a joint letter submitted today, the involved parties have notified Judge Cote that they have completed updates to the Plaintiff Fact Sheets.

    Furthermore, they have revised the health records authorization forms required for new plaintiffs joining the case.

    These adjustments are intended to address logistical challenges that have arisen and to simplify the information-gathering process for new plaintiffs.

    In response to the Plaintiffs’ intention to submit additional expert reports from two of their experts, the defendants have raised objections.

    The defendants argue that such supplementation, involving a new study, is untimely and violates Rule 26 because it was only available in a pre-print version, which differs from being formally published in a journal.

    In preparation for the upcoming Daubert hearings, Judge Cote has requested that both parties present logistical plans for the hearings.

    The defendants are advocating for an extended, week-long hearing to allow them additional time to challenge the scientific evidence.

    On the other hand, the plaintiffs are advocating for a more streamlined process and have proposed that Judge Cote identify in advance the experts she deems essential to hear from.

    October 2nd 2023:

    Both parties have informed Judge Cote in a joint letter this morning that they have finished revising the Plaintiff Fact Sheets and health records authorization forms for new plaintiffs. These changes aim to streamline the information gathering process and address logistical issues.

  • September 2023 Updates:

    September 22nd, 2023:

    In the Tylenol autism class action lawsuit, the outcome hinges on Daubert challenges related to the admissibility of expert witnesses on causation. If the plaintiffs’ causation experts are excluded, the lawsuits may end in federal courts. Both sides have filed objections to each other’s experts.

    These objections focus on issues like methodology, qualifications, and relevance. The Daubert hearings will determine whether these experts’ testimonies are admissible, with the aim of discrediting the opposing side’s experts.

    September 18th, 2023: 

    The Tylenol autism class action MDL had 136 pending cases in June 2023, but it has since grown to 265, nearly doubling in size over the last several months. However, this number does not accurately represent the situation, as there are more than 100,000 Tylenol claims awaiting a decision from Judge Cote before proceeding with lawsuits.

    September 11, 2023:

    Earlier in the year, Judge Cotes, presiding over the Tylenol Autism litigation, requested the FDA’s input on the plaintiffs’ proposal to add new cautionary labels to Tylenol containers. The decision was scheduled for September 15, but the FDA released a statement a week early expressing its reluctance to get involved in pharmaceutical litigation. Consequently, the FDA will not provide its perspective on the plaintiffs’ request for warning labels.

    This development could have had a significant impact on the plaintiffs’ legal case. If the FDA had supported their request, it would have presented a strong indication in court that the government concurs with the idea that Tylenol can lead to autism in infants. Conversely, if the FDA had opposed the plaintiffs’ request, it would have signaled a contrary viewpoint, potentially leading Judge Cote to consider dismissing all of the cases.

    September 1st, 2023:

    Judge Cote sought input from the FDA in April regarding the warning issue at the core of the Tylenol autism class action lawsuits. The objective being to assess if the warnings proposed by the plaintiffs should be incorporated into acetaminophen labels, considering the validity of these warnings based on current scientific evidence regarding the risk of autism or ADHD in children.

    Represented by the U.S. Attorney for the Southern District of New York, the FDA asked for an extension, moving the response deadline to September 15, 2023.

  • August 2023 Updates:

    August 30, 2023

    Judge Cote, presiding over the Tylenol Autism MDL, will decide on the Daubert motions by September 19. This decision could greatly affect which direction the legal proceedings go.

    Daubert motions involve requests to exclude expert testimonies in court. If Judge Cote rules favorably for the plaintiffs and allows the admission of their expert testimonies, it would strengthen the plaintiffs’ arguments.

    In addition to the Daubert decision forthcoming,  the FDA is obligated to soon disclose its stance on the litigation concerning warning labels for Tylenol. This disclosure has been extended to September 15, four days before the Daubert decision is due.

    August 14th, 2023: 

    In a collective letter presented to Judge Cote, the defendants and plaintiffs within the Tylenol autism MDL have agreed that plaintiffs residing in select states will be precluded from pursuing negligent misrepresentation claims centered on omissions. Those states include the following: Arkansas, California, Colorado, Idaho, Indiana, Kentucky, Nebraska, New Hampshire, North Carolina, North Dakota, Ohio, South Dakota, Tennessee, Texas, and Wyoming.

  • July 2023 Updates:

    July 18th, 2023

    In the past month, the Tylenol autism class action MDL in the Southern District of New York saw a significant increase with 64 new cases filed, marking the highest number of new filings since the creation of the MDL.

    Currently, there are 200 pending cases in the MDL.

    However, a substantial number of potential plaintiffs have yet to file, observing developments closely, particularly how evidentiary rulings unfold later in the year within the MDL.

    These rulings are expected to shape the course of the litigation and may influence the decision of other potential plaintiffs to join the MDL.

    July 7th, 2023

    Judge Cote is taking a proactive approach to ensure timely progress in the Tylenol lawsuits.

    Show cause orders have been issued to plaintiffs in two cases, namely Jackson v. Walmart and Swindell v. Johnson and Johnson, who have not completed required fact sheets.

    These orders demand an explanation from the non-compliant parties as to why their cases should not be dismissed for failing to fulfill their discovery obligations

    July 1st,  2023

    As the Tylenol class action progresses through 2023, several key steps lie ahead.

    Currently, the plaintiffs have submitted their expert reports, with the defendants expected to file their reports in response.

    Subsequently, the plaintiffs might present rebuttal experts, followed by expert depositions.

    Towards the end of the year, a critical hearing will take place, where Judge Cote will assess the scientific evidence linking acetaminophen to autism and ADHD.

    Depending on her determination, the case may proceed in federal court or be transferred to state court.

    The outcome of this hearing will play a significant role in shaping the course of the litigation going forward.

  • June 2023 Updates:

    June 5, 2023:

    A plaintiff has strongly objected to Johnson & Johnson’s (J&J) request for an immediate appeal of the court’s preemption and causation orders.

    The plaintiffs’ motion emphasizes that granting J&J’s plea for an immediate appeal would bring the litigation to a grinding halt for approximately a year.

    Moreover, the plaintiffs argue that this type of appeal should be considered a rare exception, and is not applicate in this specific case.

  • May 2023 Updates:

    May 9th, 2023:

    Johnson & Johnson (J&J) has requested an interlocutory appeal in the Tylenol autism class action MDL regarding the rejection of their preemption motion by Judge Cote.

    This appeal would allow J&J to seek an appellate court’s assessment of the preemption order before the case progresses further.

    Interlocutory appeals are exceptions to the general rule of appealing only after a final judgment and are granted in specific situations.

    Although the court is unlikely to approve the interlocutory appeal, as the judge aims to expedite the litigation, the issue will be fully briefed as per the set schedule.

    May 16th, 2023:

    Despite the consolidation of the Tylenol autism cases into a class action MDL over six months ago, there are currently only 124 pending cases in the MDL.

    The relatively low number can be attributed to thousands of potential plaintiffs waiting on the sidelines to observe the outcome of Daubert challenges in the MDL.

    By doing so, these plaintiffs can gauge whether the scientific evidence linking Tylenol to autism will be dismissed by the judge.

    If the evidence is deemed admissible, a surge of new cases is expected to be filed in the MDL.

    This cautious approach allows prospective plaintiffs the option to file their cases in state court if the MDL gets terminated.

  • April 2023 Updates:

    New data from the CDC indicates that the number of children in the U.S. diagnosed with autism spectrum disorder (ASD) has increased in recent years.

    The research suggests that 1 out of every 36 children in the U.S. is now diagnosed with autism or ASD.

    The judge overseeing the Tylenol Autism Multidistrict Litigation asked for proposed warning language that could be added to acetaminophen bottles.

    The plaintiffs’ attorneys have proposed a warning that states that using this product frequently during pregnancy may increase the risk of autism and attention deficit hyperactivity disorder in children.

    They recommend that pregnant women use the lowest effective dose for the shortest possible time and at the lowest possible frequency.

  • March 2023 Updates:

    March 1st, 2023

    There were 107 pending cases in the acetaminophen ADHD/autism class action litigation, an increase from the 80 cases that were pending when the class action MDL was created a few months ago.

    March 9th, 2023

    March 9th, the plaintiffs filed a memorandum opposing the motion to dismiss filed by J&J last month.

    J&J is seeking dismissal of the Tylenol lawsuits on the grounds that the federal preemption doctrine precludes them, arguing that the warning labels on Tylenol are regulated by the FDA and governed by federal law.

    However, this same argument was already rejected by Judge Cote when Walmart’s motion to dismiss was filed back in December.

    J&J will have an opportunity to file a supplemental brief in support of its motion next week, but it is expected that Judge Cote will rule quickly based on her previous decision.

  • February 2023 Updates:

    February 3rd, 2023:

    Judge Cote issued an order to increase cooperation between state and federal court cases involving Tylenol autism lawsuits, as there are related cases filed in state courts that are not included in the MDL class action lawsuit.

    February 11th, 2023:

    The parties were instructed to submit joint or competing plaintiff’s fact sheets by February 28, 2023, which will help identify common issues and patterns among the claims and select the first lawsuits to go to trial.

    February 25th, 2023:

    Judge Conte issued a new order finalizing the protocol, rules, and schedule for expert witness depositions and fact discovery, allowing the depositions to begin and leading up to a ruling on the admissibility of the plaintiffs’ causation evidence in October.

  • January 2023 Updates:

    The Tylenol litigation is ongoing, and major steps are being made by the court and Judge Cote to make it easier for those potentially impacted by Tylenol use during pregnancy to file claims directly into the MDL with the help of their attorney.

    The court is also establishing a discovery plan:

    A series of hearings and depositions that aim to establish the scientific basis of the argument that Tylenol use during pregnancy may increase the risk for certain developmental disorders.

    Contact us for a free consultation.

    You can also use the chatbot on this page to see if you qualify for legal action instantly.

Tylenol Use While Pregnant Linked to Neurological Disorders in Children

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children

Multiple research studies on over 200,000 children total have been completed, and all showed links between taking Tylenol during pregnancy and the elevated risks of autism and ADHD diagnoses, as well as other neurological disorders in children exposed.

In September 2021, a Consensus Statement from 91 doctors, scientists, clinicians, and public health officials was published in Nature Reviews Endocrinology titled “Paracetamol use during pregnancy – a call for precautionary action”.

taking Tylenol while pregnant

The new study explains that using Tylenol or other paracetamol products during pregnancy puts children at a higher risk for developing neurological disorders such as:

Tylenol and Autism Spectrum Disorder (ASD)

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD)

The possible link between prenatal acetaminophen exposure and autism has become clearer due to multiple scientific studies on infant cohorts across the world:

  • 2015:  The Danish National Birth Cohort, established by the Danish National Research Foundation, published a study that included over 64,000 children and mothers. The researchers analyzed data and found that over 50% of children diagnosed with ASD and infantile autism were born to mothers who used acetaminophen during pregnancy.
  • 2016:  Spanish researchers completed a study that included 2,644 mother-child pairs, over 40% of which used acetaminophen during pregnancy. The study found that prenatal acetaminophen exposure was associated with a greater number of autism spectrum symptoms and complex developmental disorder in male offspring and showed adverse effects on attention-related outcomes for both genders.

Tylenol and Attention Deficit Hyperactivity Disorder (ADHD)

Along with the discovery of Paracetamol’s link to increased rates of autism, studies also found that the drug’s use during pregnancy also resulted in higher rates of ADHD diagnosis.

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD)

As these research ventures are completed over years, ADHD symptoms begin to appear as the child grows older:

  • 2015:  Using the Danish National Birth Cohort, UCLA and University of Aarhus researchers concluded a further link between Acetaminophen and ADHD.
  • 2019:  Researchers from Johns Hopkins University and the Office of Epidemiology and Research at the US Department of Health and Human Services published a study on 996 mother-infant pairs from the Boston Birth Cohort. They found that cord plasma biomarkers of fetal exposure to adult acetaminophen use and cord blood samples contained a significantly increased risk of ADHD and ASD.

Tylenol and Cerebral Palsy

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy

Exposure to paracetamol and other painkillers in the womb may also lead to cerebral palsy, research shows:

Tylenol and Oppositional Defiant Disorder and Conduct Disorder

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy; Tylenol And Oppositional Defiant Disorder And Conduct Disorder

Both oppositional defiant disorder and conduct disorder are behavioral conditions exhibited in children.

The neurobehavioral impacts of Tylenol on a child during pregnancy have been found to result in disorders such as these:

  • 2014:  long-term study from UCLA, University of Arizona, Novartis Farmaceutica SA (Barcelona), and the University of Aarhus concluded that acetaminophen use during pregnancy resulted in conduct problems and behavioral problems.
  • 2018Researchers from the Netherlands found links between higher rates of oppositional-defiant disorder symptoms and paracetamol use during pregnancy.

About Tylenol and its Generic Equivalents

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy; Tylenol And Oppositional Defiant Disorder And Conduct Disorder; About Tylenol And Its Generic Equivalents

Tylenol, or acetaminophen (paracetamol), is one of the most popular over-the-counter medications for pain relief and fever in the world and is commonly used during pregnancy.

Tylenol is taken orally (pill) in a multitude of different dosage amounts depending on the intended use.

Used by millions of people, the drug is perceived as essentially harmless for the majority of the population.

The generic form of Tylenol is Acetaminophen, which is the name of the active ingredient.

Tylenol, Acetaminophen, ParacetamolTylenol is different from pain medications like Ibuprofen, Advil, and Aspirin, which are classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Acetaminophen works to only reduce fever and relieve pain.

NSAIDs reduce fever, relieve pain, and also reduce inflammation, swelling, and irritation.

Will Generic Acetaminophen Be Included in the Lawsuit? 

If you took a generic version of Tylenol, acetaminophen, paracetamol, you may still qualify for a lawsuit.

Our legal team is investigating the details of the potential case against drug manufacturers and will let potential clients know when further information becomes available.

Is Tylenol Safe to Use During Pregnancy?

Tylenol has been widely considered safe by previous research, doctors, and healthcare professionals to be used during pregnancy, but new studies have shown risks associated with the medication.

Many public health authorities state that low doses of acetaminophen should not be withheld from pregnant women or children, as there are no alternatives for the medication despite the risks posed.

The U.S. Food and Drug Administration (FDA) categorizes drugs based on their relative safety for use by pregnant women.

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy; Tylenol And Oppositional Defiant Disorder And Conduct Disorder; About Tylenol And Its Generic Equivalents; Is Tylenol Safe To Use During Pregnancy

The safest drugs are placed in Pregnancy Risk Category A, deeming no adverse risk to patients.

Acetaminophen is in Pregnancy Category B, which deems the drug “safe” for pregnant women, although “no adequate and well-controlled studies” have been performed on pregnant women using the drug.

Filing a Lawsuit

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy; Tylenol And Oppositional Defiant Disorder And Conduct Disorder; About Tylenol And Its Generic Equivalents; Is Tylenol Safe To Use During Pregnancy; Filing A Lawsuit

If you or a loved one’s child has been diagnosed with a neurological disorder such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD), you may be eligible to file a claim.

There are a few key steps to follow in order to file a successful claim.

child with autism

You must begin by gathering evidence, hiring a lawyer, and assessing damages.

Gathering Evidence for a Lawsuit

Evidence in a case involving neurological disorder caused by prenatal Tylenol, acetaminophen, or paracetamol exposure is crucial.

You must be able to prove that you took Tylenol or a generic equivalent during pregnancy and that your child was subsequently diagnosed with a neurological disorder related to documentary and scientific evidence.

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy; Tylenol And Oppositional Defiant Disorder And Conduct Disorder; About Tylenol And Its Generic Equivalents; Is Tylenol Safe To Use During Pregnancy; Filing A Lawsuit; Gathering Evidence For A Lawsuit

Evidence may include:

  • Medical records indicating Tylenol usage during pregnancy
  • Receipts for purchase of Tylenol or Acetaminophen products
  • Medical records indicating that your child was diagnosed with a related neurological disorder
  • Any notes from doctors or healthcare professionals about Tylenol use during pregnancy

Hiring a Lawyer

After gathering information and evidence for your case, contact and hire an experienced attorney to handle your Tylenol lawsuit.

A lawyer will guide you through the civil lawsuit process and keep you informed at every step of the way.

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy; Tylenol And Oppositional Defiant Disorder And Conduct Disorder; About Tylenol And Its Generic Equivalents; Is Tylenol Safe To Use During Pregnancy; Hiring a Lawyer

Law firms that have handled mass tort cases before will understand the burdens you’ve dealt with and will lend a helping hand to secure rightful compensation.

Assessing Damages

Damages in a personal injury lawsuit refer to any and all monetary and non-monetary losses associated with your case.

Tylenol-Autism-ADHD-Lawsuit-Acetaminophen-Autism-ADHD-Lawsuit-Banner-Image; Tylenol Use While Pregnant Linked To Neurological Disorders In Children; Tylenol And Autism Spectrum Disorder (ASD); Tylenol And Attention Deficit Hyperactivity Disorder (ADHD); Tylenol And Cerebral Palsy; Tylenol And Oppositional Defiant Disorder And Conduct Disorder; About Tylenol And Its Generic Equivalents; Is Tylenol Safe To Use During Pregnancy; Hiring a Lawyer; Assessing Damages

In a Tylenol case, damages may include:

  • Medical costs and bills
  • Pain and suffering, mental health effects
  • Lost wages or income
  • Loss of enjoyment of life
  • Permanent disability

TruLaw: Investigating Tylenol Neurological Disorder Claims

Our legal team is currently investigating the claims made against Tylenol manufacturers, scientific research, and more to get a better understanding on how we can best help those who’ve suffered as a result of Johnson & Johnson’s negligence to inform the public of certain risks posed by their products.

Written By:
Jessie Paluch
Jessie Paluch

Experienced Attorney & Legal SaaS CEO

With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three.  She spent the first decade of her career working as an international tax attorney at Deloitte.

In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.

In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!

Camp Lejeune Lawsuit

Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.

Tylenol Lawsuit

Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.

AFFF Lawsuit

Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.

Do You
Have A Case?

Here, at TruLaw, we’re committed to helping victims get the justice they deserve.

Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.

Would you like our help?

Helpful Sites & Resources